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Background: The National Cancer Patient Experience Survey (NCPES) 2013 includes data on 68 737 
patients from English NHS Trusts providing acute cancer services に a response rate of 64%. Patient 
responses are grouped, inter alia, by 14 types of cancer. NCPES 2013 asked about the patient 
experience of cancer research. We wanted to identify if opportunities to participate in research vary 
according to their type of cancer. 
Method: OﾐW ﾗa デｴW ヴWゲW;ヴIｴ ケ┌Wゲデｷﾗﾐゲ ┘;ゲ さ“ｷﾐIW ┞ﾗ┌ヴ Sｷ;ｪﾐﾗゲｷゲ ｴ;ゲ ;ﾐ┞ﾗﾐW SｷゲI┌ゲゲWS ┘ｷデｴ ┞ﾗ┌ 
┘ｴWデｴWヴ ┞ﾗ┌ ┘ﾗ┌ﾉS ﾉｷﾆWデﾗ デ;ﾆW ヮ;ヴデ ｷﾐ I;ﾐIWヴ ヴWゲW;ヴIｴいざ TｴW Cｴｷ-squared test was used to test for 
association between cancer site and reporting a discussion about research. 
Results: All cancers: Dﾗﾐげデ ﾆﾐﾗ┘ ヵくンХ, No 64.6%, Yes 30.1%. Results for 14 Tumour sites: YES 
Urological Cancers 15%, Skin 17%, Gynacological 27%, Head &Neck 27%, Lung 30%, Colorectal & 
Lower GI 31% Other 31%, Sarcoma 32%, Prostate 33%, Upper GI 33% Haematological 34% Breast 
35%,Bヴ;ｷﾐ わ CN“ C;ﾐIWヴゲ ンヶХが ┗;ヴｷ;デｷﾗﾐゲ ゲｷｪﾐｷgI;ﾐデ ;デ デｴW P < 0.001 level. 
Conclusion: P;デｷWﾐデゲげ ﾗヮヮﾗヴデ┌ﾐｷデｷWゲ デﾗ ヮ;ヴデｷIｷヮ;デW ｷﾐ ヴWゲW;ヴIｴ vary according to their type of cancer. 
Skin and urological canIWヴ ヮ;デｷWﾐデゲ ;ヴW ;ゲﾆWS ゲｷｪﾐgI;ﾐデﾉ┞ ﾉWゲゲ ﾗaデWﾐ デｴ;ﾐ ﾗデｴWヴゲく TｴWゲW gﾐSｷﾐｪゲ 
prompt the question: how far do these variaデｷﾗﾐゲ ヴW｡WIデ ┗;ヴｷ;デｷﾗﾐゲ ｷﾐ デｴW NIHR CRN C;ﾐIWヴ ヮﾗヴデaﾗﾉｷﾗ 
or other types of reゲW;ヴIｴ Wｪ デｷゲゲ┌W H;ﾐﾆｷﾐｪい WW ｴ;┗W SWﾏﾗﾐゲデヴ;デWS WﾉゲW┘ｴWヴW ふ;Hゲデヴ;Iデ さKWWヮｷﾐｪ 
デｴW C┌ゲデﾗﾏWヴ “;デｷゲgWSざセヱぶ ゲｷｪﾐｷgI;ﾐデ ;ゲゲﾗIｷ;デｷﾗﾐ HWデ┘WWﾐ ｴ;┗ｷﾐｪ ; SｷゲI┌ゲゲｷﾗﾐ ;ﾐS ヮ;デｷWﾐデゲげ ヴ;デｷﾐｪ 
of their care. So a further question arises: what more can be done to widen access to research to 
those groups with less access? Inequalities between cancer types are likely to attract interest from 
the new Local Clinical Research Networks, from Clinical Studies Groups, from Patient Groups 
&Cancer Charities, and from Commissioners and Cancer Peer Reviewers. 
